Exosome-mediated delivery of siRNA in vitro and in vivo

By S. El-Andaloussi, Y. Lee, S. Lakhal-Littleton, Jinghuan Li, Y. Seow, C. Gardiner, L. Álvarez-Erviti, I. Sargent, M. Wood. Nature Protocols, 2012

595 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, background): “Furthermore, it regulates the conduct of clinical trials (142).”
Engineering exosomes for targeted drug delivery (2021, methodology): “peptide (TIWMPENPRPGTPCDIFTNSRGKRASNG) shows selective binding to acetylcholine receptors and has been used to develop neuro-specific exosomes to deliver drugs to the central nervous system [47].”
Bovine milk-derived exosomes for drug delivery (2015, background): “Although the field of exosome-based therapeutics is in its infancy, the ability to engineer exosomes to display proteins, incorporate specific nucleic acid and protein cargos, load therapeutic agents, its targeted uptake and tolerance in vivo have been demonstrated to some extent [14, 15].”
Exosome Theranostics: Biology and Translational Medicine (2018, background): “For instance, some researchers have demonstrated that EVs containing the rabies viral glycoprotein show a tropism to the brain [60, 61].”